Zusammenfassung
Die Inzidenz von Melanomen hat in den letzten Jahren deutlich zugenommen. Die Anwendung der PET/CT-Diagnostik bei diesem Krankheitsbild ist um ein Vielfaches häufiger als bei anderen dermatologischen Tumoren. Vor allem hinsichtlich neuer systemischer Therapieansätze kann die PET/CT eine wichtige Rolle für eine notwendige kritische Evaluierung des Krankheitsverlaufs bzw. Therapieansprechens spielen. Das initiale Krankheitsstadium ist dabei, wie bei den meisten Tumorerkrankungen, von entscheidender Bedeutung. Darüber hinaus bestimmen Tumorgröße/-dicke, Ulzerationen, das Vorhandensein und die Anzahl von Mikrometastasen sowie Fernmetastasen über Diagnostik und Therapie mit. Gerade die Abklärung von regionalen oder Fernmetastasen war seit Beginn der klinischen PET-Nutzung eine wichtige Indikation für die PET/CT. Zunehmend rückt auch die Diagnostik des Primärtumors mit PET/CT in den Fokus.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Belhocine T, Pierard G, De Labrassine M et al. (2002) Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. The Oncologist 7: 271–278
Gambhir SS, Czernin J, Schwimmer J et al. (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42 (suppl): 1S–93 S
Holzmann H, Altmeyer P, Hor G, Hahn K (1985) Dermatologie und Nuklearmedizin. Springer, Berlin
Hor G, Maul FD, Krause BJ, Werner RJ, Baum RP, Brandhorst I, Holzmann H (1995) The skin. In: Wagner HN, Szabo Z, Buchanan JW (eds) Principles of nuclear medicine. Saunders, Philadelphia, S 1029–1033
Hor G, Werner R, Klusmann A, Baum RP, Maul BJ, Krause FD, Holzmann H (1996) Diagnostische Beitrage der Nuklearmedizin fur den Dermatologen—Eine Standortanalyse nach 15-jahriger Kooperation. H + G 71: 594–610
Iagaru A, Quon A, Johnson D et al. (2007) 2-deoxy-2-[F-18]fluoro- D-glucose positron positron emission tomography/computed tomography in the management of melanoma. Mol Imaging Biol 9: 50–57
Vidal-Sicart S, Pons F, Fuertes S et al. (2004) Is the identification of in-transit sentinel lymphnodes in malignant melanoma patients really necessary? Eur J Nucl Med Mol Imag 31: 945–949
Lee CC, Faries MB, Wanek LA, Morton DL (2009) Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 27(21): 3489–3495
Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2013) Krebs in Deutschland 2009/2010. Beitrage zur Gesundheitsberichterstattung des Bundes. Ausgabe, Berlin, 60–63. http://www.rki.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2013/krebs_ in_deutschland_2013.pdf;jsessionid = 8D65E3DB2765A1D4C6CE- 39F27AB011D8.2_cid372?__blob = publicationFile. (Zugriff: 18.03.2015)
S3 Leitlinie Melanom – 032-024l_S3_Melanom_Diagnostik_Therapie_ Nachsorge_2013-02.pdf. http://www.awmf.org/uploads/tx_szleitlinien/032-024l_S3_Melanom_Diagnostik_Therapie_ Nachsorge_2013-02.pdf
Rinne D, Baum RP, Hor G, Kaufmann R (1998) Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82(9): 1664–1671
Reinhardt MJ, Joe AY, Jaeger U et al. (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24(7): 1178–1187
Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN (2014) Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surg Oncol 23(1):11–16. doi:10.1016/j.suronc.2014.01.002
Pfluger T, Melzer HI, Schneider V et al. (2011) PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging 38(5): 822–831. doi:10.1007/s00259-010-1702-z
Bronstein Y, Ng CS, Rohren E et al. (2012) PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. Am J Roentgenol 198(4): 902–908. doi:10.2214/AJR.11.7280
Jouvet JC, Thomas L, Thomson V et al. (2014) Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol 28(2): 176–185
Xing Y, Bronstein Y, Ross MI et al. (2011) Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of Melanoma Patients: a Meta-analysis. J Natl Cancer Inst 103(2): 129–142. doi:10.1093/jnci/djq455
Wagner T, Chevreau C, Meyer N, Mourey L, Courbon F, Zerdoud S (2012) Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases. J Eur Acad Dermatol Venereol 26(11): 1431–1435. doi:10.1111/j.1468–3083.2011.04312.x
Etchebehere ECSC, Romanato JS, Santos AO, Buzaid AC, Camargo EE (2010) Impact of [F-18] FDG-PET/CT in the restaging and management of patients with malignant melanoma. Nucl Med Commun 31(11): 925–930. doi:10.1097/MNM.0b013e32833f6137
Danielsen M, Hojgaard L, Kjar A, Fischer BM (2013) Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. Am J Nucl Med Mol Imaging 4(1): 17–28
Beasley GM, Parsons C, Broadwater G et al. (2012) A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg 256(2): 350–356. doi:10.1097/SLA.0b013e318256d1f5
Sanghera B, Wong WL, Sonoda LI et al. (2014) FLT PET-CT in evaluation of treatment response. Indian J Nucl Med 29(2): 65–73
Aarntzen EHJG, Srinivas M, De Wilt JHW et al. (2011) Early identification of antigen-specific immune responses in vivo by [18F]- labeled 3’-fluoro-3’-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A 108(45): 18396–18399. doi: 10.1073/pnas.1113045108
Baudy AR, Dogan T, Flores-Mercado JE et al. (2012) FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973. EJNMMI Res 2(1): 22. doi:10.1186/2191-219X-2-22
Beaino W, Anderson CJ (2014) PET imaging of very late antigen-4 in melanoma: comparison of 68 Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. J Nucl Med 55(11): 1856–1863
Qin C, Liu H, Chen K et al. (2014) Theranostics of Malignant Melanoma with 64CuCl2. J Nucl Med 55(5): 812–817. doi: 10.2967/jnumed.113.133850
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mohnike, W., Hör, G., Hertel, A. (2016). Dermatologische Tumoren. In: Mohnike, W., Hör, G., Hertel, A., Schelbert, H. (eds) PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48842-3_10
Download citation
DOI: https://doi.org/10.1007/978-3-662-48842-3_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-48841-6
Online ISBN: 978-3-662-48842-3
eBook Packages: Medicine (German Language)